Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24326321 | 1.00 | TSHR (0.42) | TSHRCA2SIRT2GLAALDH1A1 | |
| SCHEMBL15786354 | 0.90 | CA2 (0.44) | TSHRCA2SIRT2ALDH1A1NPSR1 | |
| SCHEMBL28924707 | 0.90 | CA2 (0.44) | TSHRCA2SIRT2ALDH1A1NPSR1 | |
| SCHEMBL25961260 | 0.90 | CA2 (0.44) | TSHRCA2SIRT2ALDH1A1NPSR1 | |
| SCHEMBL8869148 | 0.82 | TBXA2R (0.43) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL8869137 | 0.82 | TBXA2R (0.43) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL4528384 | 0.80 | CA2 (0.46) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL4526320 | 0.80 | CA2 (0.46) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL21135291 | 0.80 | CA2 (0.48) | TSHRCA2ALDH1A1NPSR1TMEM97 | |
| SCHEMBL8917799 | 0.80 | CA2 (0.41) | TSHRCA2ALDH1A1NPSR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322518-B1 | Method of manufacture of 1,3-dioxolane and 1,3-oxathiolane nucleosides | GILEAD SCIENCES INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2322518-A1 | Method of manufacture of 1,3-dioxolane and 1,3-oxathiolane nucleosides | Gilead Sciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-6939965-B2 | Process of manufacture of 1,3-oxathiolane nucleosides using titanium trichloride mono-isopropoxide | GILEAD SCIENCES, INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1535921-A1 | Method of manufacture of 1,3-oxathiolane nucleosides | GILEAD SCIENCES, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1361223-B1 | Method of manufacture of 1,3-oxathiolane nucleosides | GILEAD SCIENCES INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1104415-B1 | METHOD OF MANUFACTURE OF 1,3-OXATHIOLANE NUCLEOSIDES | GILEAD SCIENCES INC (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1361223-A1 | Method of manufacture of 1,3-oxathiolane nucleosides | Triangle Pharmaceuticals Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030144532-A1 | Method of manufacture of 1,3-oxathiolane nucleosides | GILEAD SCIENCES, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6576776-B1 | Method of manufacture of 1,3-oxathiolane nucleosides | TRIANGLE PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-6518425-B1 | A process for producing a 1,3-oxathiolane nucleoside comprising reacting a 5-halo-2-protected-oxymethyl-1,3-oxathiolane with a silylated purine or pyrimidine without the addition of a Lewis acid or an additional base to the reaction | EMORY UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144532-A1 | Method of manufacture of 1,3-oxathiolane nucleosides | NUDT1, PNP, TYMP | TSHR 3447/4885CA2 4386/4885SIRT2 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.